RAPID EFFECT OF TOCILIZUMAB IN RHEUMATOID ARTHRITIS
https://doi.org/10.14412/1995-4484-2011-55
Abstract
Objective: to evaluate the efficiency of two tocilizumab (TCZ) infusions in patients with rheumatoid arthritis (RA).
Subjects and methods. The study enrolled 43 middle-aged patients with RA, mainly female ones (male/female ratio 10:33) with a RA history of 5.6±4.74 years, who were seropositive for rheumatoid factor and anti-cyclic citrullinated peptide antibodies and had high disease activity scores (DAS 28 - 6.3) prior to TCZ treatment and received disease-modifying anti-inflammatory agents, including methotrexate and glucocorticoids without providing any therapeutic effect. Therapy with TCZ was performed by the standard regimen; the dose of the drug was 8 mg/kg per infusion. The therapeutic effectiveness was evaluated 4 weeks after each infusion and by the time course of changes in DAS 28, its individual components, and health assessment questionnaire scores.
Results. After the first TCZ infusion, the patients with RA were found to have significant positive changes in the major clinical and laboratory parameters of disease activity (p < 0.0001 in all cases) that progressed after the second TCZ infusion. There were reductions in DAS 28 to 4.1 and 3.1 after each infusion and in the number of patients with high disease activity and an increase in that of patients with low/moderate one. At the same time, more than 20% of the patients developed remission after the second infusion. A good therapeutic effect was noted in 14 and 51% of the patients after the first and second infusions, respectively.
Conclusion. TCZ exerts a rapid statistically significant positive effect on the major clinical and laboratory parameters of RA activity.
Subjects and methods. The study enrolled 43 middle-aged patients with RA, mainly female ones (male/female ratio 10:33) with a RA history of 5.6±4.74 years, who were seropositive for rheumatoid factor and anti-cyclic citrullinated peptide antibodies and had high disease activity scores (DAS 28 - 6.3) prior to TCZ treatment and received disease-modifying anti-inflammatory agents, including methotrexate and glucocorticoids without providing any therapeutic effect. Therapy with TCZ was performed by the standard regimen; the dose of the drug was 8 mg/kg per infusion. The therapeutic effectiveness was evaluated 4 weeks after each infusion and by the time course of changes in DAS 28, its individual components, and health assessment questionnaire scores.
Results. After the first TCZ infusion, the patients with RA were found to have significant positive changes in the major clinical and laboratory parameters of disease activity (p < 0.0001 in all cases) that progressed after the second TCZ infusion. There were reductions in DAS 28 to 4.1 and 3.1 after each infusion and in the number of patients with high disease activity and an increase in that of patients with low/moderate one. At the same time, more than 20% of the patients developed remission after the second infusion. A good therapeutic effect was noted in 14 and 51% of the patients after the first and second infusions, respectively.
Conclusion. TCZ exerts a rapid statistically significant positive effect on the major clinical and laboratory parameters of RA activity.
About the Authors
E Yu PanasyukV N Amirdzhanova
E N Aleksandrova
E G Gubar
G V Lukina,
E L Luchikhina,
E S Tsvetkova
T N Gavva,
E F Fedorenko,
A S Avdeyeva
N V Klimova
E L • Nasonov
References
1. <div><p>Smolen J.S., Aletaha D., Bijsma J.W.J. et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.</p><p>Smolen J.S., Landewe R., Breedveld F.C. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.</p><p>Насонов Е.Л., Каратеев Д.Е., Балабанова Р.М. Ревматоидный артрит. В кн.: Ревматология. Национальное руководство. Под ред. Е.Л. Насонова, В.А. Насоновой. М.: ГЭОТАР-Медиа, 2008;290-331.</p><p>Smolen J.S., Aletaha D., Koeller M. et al. New therapies for treatment of rheumatoid arthritis. Lancet 2007;370:1861-71.</p><p>Van Vollenhoven R.F. Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatol 2009;5:531-41.</p><p>Furst D.E., Keystone E.C., Fleischmann R. et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. Ann Rheum Dis 2010;69(Suppl II):i2-i29.</p><p>Dayer J.M., Choy E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology 2010;49:15-24.</p><p>Assier E., Boissier M.-C., Dayer J.-M. Interleukin-6: from identification of the cytokine to development of targeted treatments. Joint Bone Spine 2010;77(6):532-6.</p><p>Melamud C.J. Recent advances in neutralizing the IL-6 pathway in arthritis. Open Access Rheum Res Rev 2009;1:133-50.</p><p>Kimura A., Kishimoto T. IL-6: regulator of Treg/IL17 balance. Eur J Immunol 2010;40:1830-5.</p><p>Насонов Е.Л. Новые подходы к фармакотерапии ревматоидного артрита: перспективы применения тоцилизумаба (моноклональные антитела к рецептору интерлейкина-6). Тер арх 2010;5:64-71.</p><p>Насонов Е.Л. Применение тоцилизу-маба (Актемры) при ревматоидном артрите. Науч-практич ревматол 2009; 3(Прил.):18-35.</p><p>Hushaw L.L., Sawaqed R., Sweis G. et al. Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis. Ther Clin Risk Manag 2010; 6:143-52.</p><p>Patel A.M., Moreland L.W. Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy. Drug Design Dev Ther 2010;4:263-78.</p><p>Nishimto N., Ito K., Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Mod Rheumatol 2010;20(3):222-32.</p><p>An M.M., Zou Z., Shen H. et al. The addition of tocilizumab to DMARD therapy for rheumatoid arthritis: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol 2010;66(1):49-59.</p><p>Singh J.A., Beg S., Lopez-Olivo M.A. Tocilizumab for rheumatoid arthritis: a Cochrane systemic review. J Rheumatol 2011;38(1):10-20.</p><p>Kremer J.L., Blanco R., Brzosko M. et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: at 1 year; results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthr Rheum 2011;63(3):609-21.</p><p>Nam J.L., Wintrop K.L., van Vollenhoven R.F. et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systemic literature rewires informing the EULAR recommendations for the management of RA. Ann Rheum Dis 2010; 69:976-86.</p><p>Salliot C., Finckh A., Katchamart W. et al. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumor necrosis factor agent: a meta-analysis. Ann Rheum Dis 2011;70(2):266-71.</p><p>Kristensen L.E., Jakobsen A.K., Bartels R.M. et al. The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systemic quantitative review of randomized controlled trials. Scand J Rheumatol 2011;40(1):1-7.</p><p>Bergman G.J., Hochberg M.C., Boers M. et al. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin Arthr Rheum 2010;39:425-41.</p><p>Campbell L., Chen C., Bhagat S.S. et al. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systemic literature review and meta-analysis of randomized controlled trials. Rheumatology 2011; 50(3):552-62.</p><p>Smolen J.S., Aletaha D. Developments in the clinical understanding of rheumatoid arthritis. Arthr Res Ther 2009;11:204.</p><p>Каратеев А.Е., Яхно Н.Н., Лазебник Л.Б. и др. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации. М.: ИМА-ПРЕСС, 2009.</p><p>Чичасова Н.В., Владимиров С.А., Имаметдинова Г.Р. и др. Функциональные исходы ревматоидного артрита при различных способах противовоспалительной терапии. Науч-практич ревматол 2010;2:30-6.</p><p>Smolen J.S., Churchill M., Rizzo W. et al. Tocilizumab treatment results in rapid improvements in the signs and symptoms to moderate-to-severe rheumatoid arthritis in four patients populations with different prior therapy exposure. Arthr Rheum 2008; 58(Suppl.):S532(989).</p><p>Beaulieu A.D., McKay J.D., Pavelka K. et al. Treatment with the humanized anti-interleukin-6 receptor antibody tocilizumab results in rapid improvements in the signs and symptoms of rheumatoid arthritis: results from a pooled analysis of clinical trial data from OPTION and TOWARD. Ann Rheum Dis 2008;67(Suppl. II):195.</p><p>Emery P., Keystone E., Tony H.-P. et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-TNF biologics: results from a 24-week multicenter randomized placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23.</p><p>Smolen J., Beaulieu A., Ruddert-Roth A. et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomized trial. Lancet 2008;371:987-97.</p><p>Genovese M.C., McKay J.D., Nasonov E.L. et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthr Rheum 2008; 58:2968-80.</p><p>Jones G., Sebba A., Gu J. et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. Ann Rheum Dis 2010;69:88-96.</p><p>Bykerk V., Ostor A., Alvaro-Gracia J.M. et al. Tocilizumab in patients with rheumatoid arthritis and an inadequate response to DMARDs and/or the TNF inhibitor therapy: ACT-SURE preliminary results. Ann Rheum Dis 2010;69(Suppl. 3):379.</p><p>Yazici Y., Curtis J.R., Ince A. et al. Efficacy and safety of tocilizumab in patients with moderate to severe RA and previous inadequate response to DMARD: the ROSE study. Arthr Rheum 2010;62(Suppl.):S754.</p><p>Hirabayashi Y., Ishii T., Harigae H. Clinical efficacy of tocilizumab in patients with active rheumatoid arthritis in real clinical practice. Rheum Int 2010;30(8):1041-8.</p><p>Nakashima Y., Kondo M., Harada H. et al. Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizum-ab in combination with methotrexate. Mod Rheumatol 2010;20:343-52.</p><p>Yamanaka H., Tanaka Y., Inoue E. et al. Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). Mod Rheumatol 2011;21(2):122-33.</p><p>Burmester G.R., Feist E., Kellner H. et al. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with avtive rheumatoid arthritis: the first phase IIIb reallife study (TAMARA). Ann Rheum Dis 2011;70(5):755-9.</p><p>Насонов Е.Л., Панасюк Е.Ю., Булдаков С.Г. и др. Эффективность и безопасность тоцилизумаба при ревматоидном артрите (промежуточные результаты российского многоцентрового исследования). Науч-практич ревматол 2010; 2:21-9.</p><p>Arnett F.C., Edworth S.M., Bloch D.A. et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthr Rheum 1988;31:315-24.</p><p>Fransen J., Stucki G., van Riel P.L.C.M. Rheumatoid arthritis measures. Arthr Rheum (Arthr Care Res) 2003; 49:S214-S224.</p><p>Fries J.F., Spitz P.W., Kraines G.G., Holman H.R. Mesurement of patient outcome in rheumatoid arthritis. Arthr Rheum 1980;23:137-45.</p><p>Troum P.M., Peterfy C.G., Kaine J.L. et al. Baseline CRP predicts early improvement in synovitis, osteitis, and erosion on MRT in RA patients with tocilizumab: results from the ACT-RAY MRI study. Arthr Rheum 2010;62(Suppl.):S49-S50</p><p>Лукина Г.В., Сигидин Я.А., Насонов Е.Л. от имени исследовательской группы. Применение инфликсимаба у больных ревматоидным артритом в клинической практике (по данным Российского регистра). Тер арх 2009;38:65-9.</p><p>Лукина Г.В., Сигидин Я.А., Насонов Е.Л. Промежуточные результаты Российского регистра применения моноклональных антител к В-лимфоцитам (препарат ритуксимаб) при ревматоидном артрите. Рус мед журн 2008;16(24):1596-601.</p><p>Kaufmann J., Feist E., Schmidt H. et al. Comparison of the efficacy of tocilizumab and TNF-α inhibitors on the DAS28 in «real life» conditions in rheumatoid arthritis (RA) patients after DMARD failure. Arthr Rheum 2010;62(Suppl.):S22.</p><p>Smolen J.S., Aletaha D. Interleukin-6 receptor inhibition with tocilizumab and attainment of remission: the role of acute phase reactants. Arthr Rheum 2011; 63(1):43-52.</p><p>Van Leeuwen M.A., van der Heijde D.M., van Rijswijk M.H. et al. Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint count, and acute phase reactant. J Rheumatol 1994;21:425-9.</p><p>Гавва Т.Н., Попкова Т.В., Смирнов А.В. и др. Связь между концентрацией СРБ, минеральной плотностью костной ткани и риском кардиоваскулярных нарушений при ревматоидном артрите. Науч-прак-тич ревматол 2008;3:30-7.</p><p>Попкова Т.В., Новикова Д.С., Новиков А.А. и др. Роль воспаления в развитии сердечно-сосудистых осложнений при ревматоидном артрите. Науч-практич ревматол 2009;3(Прил.):61-8.</p><p>Boettger M.K., Leuchtweis J., Kummel D. et al. Differential effects of locally and systemically administered soluble glycoprotein 130 on pain and inflammation in experimental arthritis. Arthr Res Ther 2010;12:R140.</p></div><br />
Review
For citations:
Panasyuk E.Yu., Amirdzhanova V.N., Aleksandrova E.N., Gubar E.G., Lukina, G.V., Luchikhina, E.L., Tsvetkova E.S., Gavva, T.N., Fedorenko, E.F., Avdeyeva A.S., Klimova N.V., • Nasonov E.L. RAPID EFFECT OF TOCILIZUMAB IN RHEUMATOID ARTHRITIS. Rheumatology Science and Practice. 2011;49(4):11-16. (In Russ.) https://doi.org/10.14412/1995-4484-2011-55
Views:
6148
Email this article 